Table 1.

Selected randomized trials in relapsed/refractory AML.

Treatment	N	2nd CR, %	Median duration 2nd CR, mo	Median OS, mo
HDAra-C vs HDAra-C +Mit	162	32 vs 44	9 vs 5	8 vs 6
EMA vs EMA + GM-CSF	72	81 vs 89	4 vs 5	9 vs 10
MAE vs MAE + G-CSF	129	25 vs 17	9 vs 10	5 vs 4
MEC vs MEC + lintuzumab	191	23 vs 29	NA	8 vs 6
HDAra-C vs HDAra-C + laromustine	178	19 vs 35	332 vs 275 d	177 vs 128 d
HDAra-C + Mit vs IDAC + Mit	186	52 vs 45	5.3 vs 3.3	5 vs NA
HDAra-C + Amsa vs HDAra-C + Mit	52	53 vs 60	11 vs 12	8 vs 11
HDAra-C vs HDAra-C + Amsa	36	14 vs 53	NA	2 vs 6
HDAra-C vs HDAra-C + Eto	131	40 vs 45	12 vs 25	5 vs 5

Karanes, et al. Leuk Res. 1999;23:787–794; Thomas, et al. Leukemia. 1999; 13: 1214–1220; Greenberg, et al. J Clin Oncol. 2004;22: 1078–1086; Feldman, et al. J Clin Oncol. 2005;23:4110–4116; Giles, et al. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 1970; Kern, et al. Leukemia. 2000; 14:226–231; Martiat, et al. Eur J Haematol. 1990;45: 164–167; Larson, et al. Br J Haematol. 1992;82:337–346; Vogler, et al. Leukemia. 1994;8: 1847–1853; Ohno, et al. Blood. 1994;83:2086–2092